InMed Pharmaceuticals Inc. has taken significant steps to reshape its corporate identity and financial structure. Following its Annual General and Special Meeting on November 4, 2026, the company announced a corporate name change and the completion of a share consolidation. These changes are pivotal as InMed transitions into Mentari Therapeutics, Inc., aiming to better align its branding with its strategic objectives.

The share consolidation, executed at a ratio of one post-consolidation share for every ten pre-consolidation shares, will reduce the total number of outstanding shares from approximately 5.5 million to about 549,374. This move is intended to enhance the company's market position and appeal to potential investors, particularly in the competitive pharmaceutical preparations sector.

Background

InMed Pharmaceuticals Inc. is a pharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet medical needs. The company operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. InMed is listed on the Nasdaq under the ticker symbol INM.

What the Filing Says

According to the SEC filing (accession number 0001062993-26-005760), the company reported the results of its 2026 Annual General and Special Meeting, where shareholders approved various proposals, including the name change and share consolidation. The filing states, "Each item of business voted on at the Meeting was approved by the shareholders." This indicates a strong consensus among shareholders regarding the company's new direction.

Impact

The changes announced by InMed may significantly affect its shareholders and the broader pharmaceutical industry. The consolidation of shares is expected to improve the company's stock performance and investor perception. Additionally, the name change to Mentari Therapeutics may help the company better communicate its mission and vision to stakeholders.

What's Next

Effective November 5, 2026, the company's shares will begin trading on the Nasdaq under the new name and post-consolidation structure. The filing does not specify any further immediate actions, but the company is expected to continue its strategic initiatives following these changes.